May 31, 2026
Daraxonrasib, a KRAS‑targeting oral drug, nearly doubled median survival vs. chemotherapy in randomized trial for previously treated metastatic pancreatic cancer
A randomized clinical trial of about 500 patients with metastatic pancreatic cancer that no longer responded to prior treatment found that the experimental oral drug...